<DOC>
	<DOCNO>NCT01822756</DOCNO>
	<brief_summary>This study ruxolitinib combination gemcitabine without nab-paclitaxel administered patient advance metastatic pancreatic cancer . The study conduct two part . Part 1 study evaluate safety , tolerability pharmacokinetics ( PK ) ruxolitinib give described patient advance metastatic pancreatic cancer . A goal Part 1 identify maximally tolerate dose ( MTD ) ruxolitinib give gemcitabine without nab-paclitaxel . This dose select use Part 2 study . Part 2 study evaluate safety , tolerability , PK preliminary clinical activity ruxolitinib dose define Part 1 use combination gemcitabine without nab-paclitaxel subject advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>An Open-Label Study Ruxolitinib Given With Chemotherapy Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Male female , 18 year old Histologically cytologically confirm adenocarcinoma pancreas Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Requirements prior therapy outline : Enrollment Regimen A : receive 1 prior chemotherapy regimen advance metastatic disease ( include neoadjuvant and/or adjuvant therapy ) Enrollment Regimen B : receive prior chemotherapy advance metastatic disease ( include neoadjuvant and/or adjuvant therapy ) Adequate renal , hepatic , bone marrow function without blood product hematopoietic growth factor support : Able swallow retain oral medication Any known contraindication use gemcitabine ( enrollment Regimen A B ) nabpaclitaxel ( enrollment Regimen B ) . Evidence uncontrolled brain metastasis history uncontrolled seizure . Ongoing radiation therapy and/or radiation therapy administer within 28 day enrollment . Subjects receive radiation spine , pelvis , rib , femur discuss sponsor , extensive radiation marrow form region may compromise subject 's ability tolerate myelosuppressive chemotherapy . Subjects ongoing radiotherapyrelated toxicity eligible . Subjects participate study receipt investigational study drug occur within 28 day 5 halflives ( whichever longer ) prior first dose . Current previous malignancy within 2 year study entry , except cure basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix , noninvasive malignancy without sponsor approval . Inability swallow food condition upper GI tract precludes administration oral medication . Recent ( ≤ 3 month ) history partial complete bowel obstruction . Unwilling transfuse blood component . Known history Hepatitis B C infection HIV infection . Presence ≥ Grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>